FDA approves AstraZeneca's Epanova, label update for Teva's Synribo; Researchers head to Twitter to identify drug problems;

> The FDA has green-lighted AstraZeneca's ($AZN) Epanova as a treatment for severe hypertriglyceridaemia in adults. Release

> The FDA has approved a label change for Teva's ($TEVA) Synribo injection that allows for home administration. Release

> A 6-week marketing suspension on Ariad's ($ARIA) chronic myeloid leukemia drug Iclusig has not negatively impacted how physicians view the drug, a survey found. More

> The U.S. diabetes market will reach $25 billion by 2020, with Sanofi ($SNY), Novo Nordisk ($NVO) and Eli Lilly ($LLY) leading the way, a new report says. Release

> An FDA panel will meet in October to review the risks of psychiatric and behavioral side effects associated with Pfizer's ($PFE) antismoking med Chantix. More

And Finally... Researchers have found that tapping into Twitter to read patient posts describing medication side effects could help them identify problems with drugs sooner. Story

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.